Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Orthocell Limited

Capitalization 22Cr 16Cr 14Cr 12Cr 12Cr 22Cr 1.47TCr 148.2Cr 59Cr 700.35Cr 60Cr 58Cr 2.53TCr P/E ratio 2026 *
-
P/E ratio 2027 * -
Enterprise value 18Cr 13Cr 11Cr 10Cr 9.57Cr 17Cr 1.18TCr 119.26Cr 47Cr 563.61Cr 48Cr 47Cr 2.03TCr EV / Sales 2026 *
13x
EV / Sales 2027 * 7.79x
Free-Float
75.86%
Yield 2026 *
-
Yield 2027 * -
1 day+0.61%
1 week-8.33%
Current month-13.16%
1 month-15.82%
3 months-21.43%
6 months-25.68%
Current year-23.96%
1 week 0.77
Extreme 0.77
0.9
1 month 0.77
Extreme 0.77
1
Current year 0.77
Extreme 0.77
1.16
1 year 0.77
Extreme 0.77
1.7
3 years 0.32
Extreme 0.32
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Chief Tech/Sci/R&D Officer - 01/04/2024
Director TitleAgeSince
Director/Board Member - 01/11/2023
Chairman - 01/06/2023
Director/Board Member 60 08/03/2023
Change 5d. change 1-year change 3-years change Capi.($)
+0.61%-8.33%-31.82%+114.29% 16Cr
-3.45%-7.91%-6.80%-11.77% 18TCr
-2.61%-3.37%-3.48%+110.72% 18TCr
-3.41%-6.89%-8.23%-21.76% 14TCr
-1.72%-6.63%-29.32%+43.17% 10TCr
-0.71%-3.63%-25.60%-20.25% 5.08TCr
-0.58%+0.67%+23.27%+10.23% 4.94TCr
-2.62%-8.46%+6.13%+13.29% 3.48TCr
-3.67%-9.34%-16.57%-8.30% 3.31TCr
-2.79%-5.41%-6.78%-18.27% 3.26TCr
Average -2.05%-4.70%-9.92%+21.13% 8.01TCr
Weighted average by Cap. -2.63%-3.55%-8.41%+22.16%

Financials

2026 *2027 *
Net sales 1.39Cr 98.59L 85.53L 77.33L 73.83L 1.34Cr 91Cr 9.2Cr 3.65Cr 43Cr 3.7Cr 3.62Cr 156.98Cr 2.41Cr 1.71Cr 1.48Cr 1.34Cr 1.28Cr 2.33Cr 157.82Cr 16Cr 6.34Cr 75Cr 6.41Cr 6.28Cr 272.17Cr
Net income - -
Net Debt -4.37Cr -3.1Cr -2.69Cr -2.43Cr -2.32Cr -4.22Cr -286.17Cr -29Cr -11Cr -136.73Cr -12Cr -11Cr -493.53Cr -3.61Cr -2.56Cr -2.22Cr -2.01Cr -1.92Cr -3.49Cr -236.4Cr -24Cr -9.49Cr -112.95Cr -9.61Cr -9.4Cr -407.7Cr
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
12/26/12 0.8250 $ +0.61% 2,26,380
11/26/11 0.8200 $ -1.20% 2,12,293
10/26/10 0.8300 $ +3.75% 3,43,481
09/26/09 0.8000 $ -9.60% 13,65,990
06/26/06 0.8850 $ -1.12% 3,46,239
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8250AUD
Average target price
1.330AUD
Spread / Average Target
+61.21%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW